ARCHIVES

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

This article is from The Cancer Letter archive.

Vol. 31 No. 16 | April 22, 2005

Download PDF Visit The Full Archive

Related Articles

OMB Restrictions On Reprogramming Could Result In Inefficient Last Minute Spending By Institutes

September 13, 1985

Course On Human Research Protections Goes Online @ Cancer.Gov.

January 26, 2001

Congress Deluged With Protests From Biomedical Researchers Over Grants Reduction, Budget Cuts

February 15, 1985

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

May 7, 2004

Trastuzumab Increases Risks Of Congestive Heart Failure

August 31, 2012

NIH Funding Opportunity: Outstanding Investigator Award In Cancer Research Available

July 11, 2014